Erimos Pharmaceuticals Announces Phase I/Phase II Study of Terameprocol (EM-1421) In Conjunction with New Approaches to Brain Tumor Therapy (NABTT) Consortium
RALEIGH, N.C.--(BUSINESS WIRE)--Erimos Pharmaceuticals, a rapidly emerging company focused primarily on the discovery, development and commercialization of cancer drugs, announced today that patient dosing has commenced for its lead product candidate, terameprocol (EM-1421), for the treatment of recurrent high grade glioma brain tumors that are unresponsive to conventional therapy.